Intercept shares tumble on concerns over NASH drug prospects
(Reuters) – Shares of Intercept Pharmaceuticals Inc fell 16% on Monday over concerns about the prospects of the company’s drug to treat a type of fatty liver disease after the regulator’s advisory panel voted to defer an accelerated approval. A panel of advisers to the U.S. Food and Drug Administration said on Friday study data suggested that the benefits of Intercept’s drug, obeticholic acid (OCA), did not outweigh the risks […]